Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 7/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464447 | 0.90 | HSD11B1 (0.39) | WDR5KDM4EHSD11B1SYK | |
| SCHEMBL19925142 | 0.90 | HSD11B1 (0.39) | WDR5KDM4EHSD11B1SYK | |
| SCHEMBL29464453 | 0.90 | HSD11B1 (0.39) | WDR5KDM4EHSD11B1SYK | |
| SCHEMBL19925097 | 0.90 | HSD11B1 (0.39) | WDR5KDM4EHSD11B1SYK | |
| SCHEMBL19925197 | 0.88 | GHSR (0.39) | SCN1ASCN8AGHSRWDR5HSD11B1 | |
| SCHEMBL29464302 | 0.88 | GHSR (0.39) | SCN1ASCN8AGHSRWDR5HSD11B1 | |
| SCHEMBL29464367 | 0.88 | GHSR (0.39) | SCN1ASCN8AGHSRWDR5HSD11B1 | |
| SCHEMBL19925195 | 0.88 | GHSR (0.39) | SCN1ASCN8AGHSRWDR5HSD11B1 | |
| SCHEMBL19927776 | 0.88 | GHSR (0.39) | SCN1ASCN8AGHSRWDR5HSD11B1 | |
| SCHEMBL19927803 | 0.87 | GHSR (0.37) | SCN1ASCN8AGHSRWDR5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | FFAR2 2079/4885SCN1A 32/4885SCN8A 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.